Cargando…

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

BACKGROUND: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, li...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Prins, Louise, Raap, Ulrike, Mueller, Tara, Schmid-Grendelmeier, Peter, Haase, Christiane H., Backer, Vibeke, Fokkens, Wytske, Benoist, Linda B., Prokopakis, Emmanuel, Doulaptsi, Maria, Hopkins, Claire, Claeys, Nele, Teeling, Thijs, Cypers, Lindsay, Cools, Leen, Bjermer, Leif H., Diamant, Zuzana, Wahn, Ulrich, Scadding, Glenis, Bachert, Claus, Walther, Peter, Patel, Sunni R., Van Staeyen, Elizabeth, Hellings, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Allergy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234878/ https://www.ncbi.nlm.nih.gov/pubmed/35769567 http://dx.doi.org/10.3389/falgy.2022.889221

Ejemplares similares

Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement
por: Scadding, Glenis K., et al.
Publicado: (2020)

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm
por: Scadding, Glenis Kathleen, et al.
Publicado: (2021)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
por: Hellings, P. W., et al.
Publicado: (2023)

Corrigendum: Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
por: Doulaptsi, Maria, et al.
Publicado: (2021)

Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA
por: Seys, Sven F., et al.
Publicado: (2020)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden
por: Doulaptsi, Maria, et al.
Publicado: (2018)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

Clinical and daily respiratory care and clinical trials within the COVID-19 era
por: Diamant, Zuzana, et al.
Publicado: (2020)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

The launch of the European Clinical Respiratory Journal, the scientific forum of the Nordic Respiratory Academy
por: Bjermer, Leif, et al.
Publicado: (2014)

The ‘GA²LEN Sinusitis Cohort’: an introduction
por: Vandeplas, Griet, et al.
Publicado: (2015)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment
por: Hoffmans, Ruth, et al.
Publicado: (2018)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Response to Letter]
por: Fifer, Simon, et al.
Publicado: (2023)

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement
por: Hellings, P. W., et al.
Publicado: (2019)

Editorial: Insights in rhinology: 2021/22
por: Smith, Peter Kenneth, et al.
Publicado: (2023)

Endotype-driven treatment in chronic upper airway diseases
por: De Greve, Glynnis, et al.
Publicado: (2017)

Allergen provocation tests in respiratory research: building on 50 years of experience
por: Gauvreau, Gail M., et al.
Publicado: (2022)

Quality of life and use of medication in chronic allergic and non-allergic rhinitis patients
por: Segboer, Christine, et al.
Publicado: (2013)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_250rbg0rgalrlbuqkrgegm1nks